Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.
The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age is 18-75 years old, and gender is unlimited;
- •HCC was confirmed by pathological or clinical examination;
- •Patients with stage CNLCIII, IV primary HCC who are receiving second-line treatment / unable to receive existing treatments, or CNLCI and II of primary HCC patients who are unable to receive existing treatments;
- •Male subjects with partner women of childbearing age must have reliable, effective methods of contraception starting from the signing of the informed consent form until 120 days after the last dose of the study drug. Male subjects with a pregnant spouse must use condoms without other contraceptive methods;
- •Participants volunteered to join the study, signed an informed consent, had good compliance, and cooperated with the follow-up.
排除标准
- •Gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, or hepatorenal syndrome;
- •Accept other cellular or immune clinical experiments within 8 weeks before enrollment;
- •Immunological deficiency, a known immunosuppressive disease or HIV;
- •Active infection, unexplained fever;
- •Serious or unstable heart, lung, kidney and hematopoietic system diseases;
- •Autoimmune diseases, such as rheumatoid arthritis;
- •Neurological diseases, diffuse leptomeningeal diseases; combined with neurodegenerative diseases;
- •Hormone use during cell therapy: dexamethasone dose exceeds 2mg / day during immunotherapy;
- •Pregnant or lactating women;
- •The subject had a known history of psychotropic substance abuse or drug use; he had stopped drinking Patients can be enrolled; 11 In the judgment of the investigator, the subject has other factors that may cause the forced termination of the study, such as other serious diseases or serious abnormal laboratory examination or other family or social factors that will affect the subject's safety of the subject, or the collection of trial data and samples.
研究组 & 干预措施
GDKM-100 injection
In this trial, the patients will receive multiple high-activity γδ T cell immunotherapies.The trial is divided into two parts: Part 1 is a multiple-dose escalation trial consisting of 3 dose groups (2×10^8 cells/person, 5×10^8 cells/person, 10×10^8 cells/person at 1-3 infusion, 4-6 infusion and 7-9 infusion), with 9 patients planned to be enrolled. Part 2 is a single dose trial in which doctor and the PI evaluates whether to give the rest patients to receive the 10×10^8 cells/person infusions based on available safety data.
The check indexes are CT scan，intestinal flora detection and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
干预措施: GDKM-100 injection (Biological)
结局指标
主要结局
Overall Survival
时间窗: Up to 16months
From the date of entry into the clinical study until death from any cause
The change of performance status score
时间窗: up to approximately 16months
In medicine(oncology and Other fields), performance status is an attempt to Quantify cancer patients' general well-being and activities of daily life.This measure is used to determine whether they can receive chemotherapy, whether dose adjustment is necessary，and as a measure for the required intensity of palliative care. It is also used in oncological randomized controlled trials as a measure of quality of life. PS scores range from 1 to 5,with Higher PS score indicating worse prognosis.
The Child-Pugh score
时间窗: up to approximately 16months
The Child-Pugh score is a system for assessing the prognosis-including the required strength of treatment and necessity of liver transplant-of chronic liver disease. It provides a forecast of the increasing severity of liver disease and expected survival rate.Child-Pugh scores range from 5 to 15, with higher scores indicating worse prognosis.Class A: 5-6, Class B: 7-9, Class C: 10-15 (minimum 5, maximum 15;)
次要结局
- PFS（Progression-Free Survival )(up to approximately 16months)
- TTP（time to disease progression )(up to approximately 16months)
- DoR(duration of remission )(up to approximately 16months)
- ORR（objective remission rate ）(up to approximately 16months)
- DCR (disease control rate)(up to approximately 16months)